Xortx Therapeutics announced the company has initiated a precision medicine program. On August 29, Xortx announced that independent peer-reviewed research reported that genetic factors are linked to the over-expression of xanthine oxidase and play a role in several diseases, including kidney disease. These ground-breaking findings provide an opportunity to expand the company’s programs and approach by combining genetic diagnostics focused on treating kidney and diseases such as sepsis by inhibiting XO with xanthine oxidase inhibition targeting individuals most in need. Recent pioneering discoveries provide Xortx with the opportunity to develop diagnostics that identify specific genetic factors. These diagnostic tools alongside Xortx’s expertise at developing unique formulations of uric acid lowering agents and XO inhibitors will permit Xortx to tailor treatments to subpopulations of individuals that have common susceptibility or similar response to a particular drug.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio